For the quarter ending 2026-03-31, PVLA has $263,759K in assets. $31,446K in debts. $206,394K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 206,394 | 57,982 | 63,567 | 70,433 |
| Accounts receivable | - | 0 | 0 | 0 |
| German research and development tax credit receivable | - | 0 | 2,216 | 1,978 |
| Short-term investments | 55,459 | - | - | - |
| Prepaid expenses and other current assets | 1,378 | 1,005 | 1,154 | 1,336 |
| Total current assets | 263,231 | 58,987 | 66,937 | 73,747 |
| Operating lease right-of-use assets, net | 528 | 572 | - | - |
| Total assets | 263,759 | 59,559 | 66,937 | 73,747 |
| Accounts payable | 5,443 | 4,595 | 3,481 | 4,557 |
| Derivative liabilities - contingent value right liability | 0 | 2,196 | 2,216 | 1,978 |
| Current portion of operating lease liability | 209 | 202 | - | - |
| Accrued expenses and other current liabilities | 3,463 | 4,351 | 4,615 | 3,081 |
| Total current liabilities | 9,115 | 11,344 | 10,312 | 9,616 |
| Long-term portion of operating lease liability | 375 | 431 | - | - |
| Royalty agreement liability | 19,799 | 17,760 | 16,021 | 14,511 |
| Derivative liabilities - royalty agreement | 2,157 | 2,041 | 1,922 | 1,840 |
| Total liabilities | 31,446 | 31,576 | 28,255 | 25,967 |
| Common stock, 0.001 par value 200,000,000 shares authorized 14,313,659 and 12,380,933 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 14 | 12 | 11 | 11 |
| Additional paid-in capital | 383,421 | 163,338 | 161,303 | 159,271 |
| Accumulated other comprehensive (loss) income | 95 | 83 | 104 | -111 |
| Accumulated deficit | -151,217 | -135,450 | -122,736 | -111,391 |
| Total stockholders' equity | 232,313 | 27,983 | 38,682 | 47,780 |
| Total liabilities and stockholders' equity | 263,759 | 59,559 | 66,937 | 73,747 |
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)